Anzeige
Mehr »
Samstag, 16.05.2026 - Börsentäglich über 12.000 News
Entsteht hier gerade der nächste AI-Infrastruktur-Highflyer?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14Y0U | ISIN: US6283411097 | Ticker-Symbol: N/A
1-Jahres-Chart
ONCOTELIC THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ONCOTELIC THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur ONCOTELIC THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrOncotelic Therapeutics GAAP EPS of $0.003
FrOncotelic Therapeutics, Inc.: Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress290Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biotechnology company focused on oncology, AI-enabled...
► Artikel lesen
DoOncotelic Therapeutics, Inc. - 10-Q, Quarterly Report1
MiOncotelic Therapeutics, Inc.: Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle Formulation of Everolimus125SAN DIEGO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano and Oncotelic (OTCQB: OTLC) today announced that the first patient has been dosed in the Phase 1b clinical trial of Sapu003...
► Artikel lesen
06.05.Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer's Disease191AGOURA HILLS, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a late-stage clinical biopharmaceutical company focused...
► Artikel lesen
ONCOTELIC THERAPEUTICS Aktie jetzt für 0€ handeln
05.05.Oncotelic Therapeutics, Inc. - 8-K, Current Report-
24.04.Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy171AGOURA HILLS, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology and rare diseases...
► Artikel lesen
23.04.Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation1
21.04.Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution2
16.04.Oncotelic Therapeutics GAAP EPS of $0.598
16.04.Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress457AGOURA HILLS, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical-stage biopharmaceutical company developing drugs...
► Artikel lesen
16.04.Oncotelic Therapeutics, Inc. - 8-K, Current Report6
15.04.Oncotelic Therapeutics, Inc. - 10-K, Annual Report-
10.04.Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space1
06.04.Nightfood Holdings Inc.: Nightfood Holdings, Inc. (dba TechForce Robotics) Announces Strategic Joint Development Agreement with Oncotelic Therapeutics155TEMECULA, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- via IBN - Nightfood Holdings, Inc., (OTCQB: NGTF) doing business as TechForce Robotics, Inc., ("TechForce" or the "Company"), today announced the...
► Artikel lesen
02.04.Oncotelic und TechForce: Partnerschaft für KI-gestützte Robotik-Plattform1
02.04.Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform150LOS ANGELES, April 02, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company"), a clinical-stage biotechnology company focused on oncology and AI-driven solutions...
► Artikel lesen
28.03.Oncotelic Therapeutics, Inc. - 8-K, Current Report-
24.03.Oncotelic Therapeutics, Inc.: Sapu Nano to Launch Deciparticle Platform and Present Clinical Pipeline at BIO-Europe Spring 20261
23.03.Oncotelic Therapeutics, Inc.: Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting2
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1